Antibody-Drug Conjugates: What the Antibody, Linker, and Payload Each Do

An antibody-drug conjugate joins three engineered parts: an antibody that finds a tumor marker, a chemical linker that holds a potent toxin during transit, and a payload that kills the cell once inside. The design is elegant, but the mechanism alone does not tell you how much benefit a given agent has proven. Approved conjugates span a wide range of evidence, from an early accelerated approval that was later withdrawn to phase 3 trials showing clear overall-survival gains. Learning what each component does makes it easier to separate a promising idea from a proven treatment.

The problem an ADC is trying to solve

Traditional chemotherapy circulates through the whole body and harms fast-dividing healthy tissue along with the tumor, which limits how much drug a person can tolerate. The premise of an antibody-drug conjugate is to keep a very potent cell-killing molecule tethered to an antibody until it reaches the tumor, then release it locally. A 2023 review of approved ADCs in the journal Cancers frames each of the three parts as an engineering tradeoff rather than a solved problem, and that framing is a useful corrective to marketing language that treats "targeted" as a guarantee of precision.

The antibody: address label, not warhead

The antibody makes up the great majority of the conjugate's mass and supplies the targeting. It recognizes a protein that is more abundant on tumor cells than on normal tissue, such as HER2 on some breast cancers, CD33 on myeloid leukemia cells, Nectin-4 on urothelial cancer, or Trop-2 across several solid tumors. Two points are easy to miss. First, "more abundant" is not the same as "exclusive," so the target protein usually appears on some healthy cells too, which is one source of side effects. Second, the antibody itself is mostly a delivery vehicle here; the killing is done by the payload, so a well-chosen target matters more than antibody potency on its own.

The linker: the part that decides where the drug is released

The linker is the chemical bridge between antibody and payload, and it carries more of the design burden than its size suggests. Cleavable linkers are built to break apart in response to conditions found inside or near tumor cells, such as an acidic environment, specific enzymes, or the reducing chemistry of the cell interior. Non-cleavable linkers stay intact and only release payload after the whole antibody is digested inside the cell's lysosome. Non-cleavable designs tend to be more stable in the bloodstream, which can reduce off-target release, while cleavable designs allow a different behavior that turns out to matter clinically: the bystander effect.

The payload: potency measured in fractions of a molecule

The payload is a cytotoxic drug far too toxic to give on its own. The review groups the common payloads into two families: microtubule inhibitors such as the auristatins (MMAE) and maytansinoids (DM1, DM4), and DNA-damaging agents such as calicheamicins and topoisomerase I inhibitors like the deruxtecan and SN-38 payloads. A related number is the drug-to-antibody ratio (DAR), the average count of payload molecules carried per antibody. The review describes an ideal range of roughly two to four: too few and the conjugate underperforms, too many and the antibody can become unstable, clear from the body faster, and lose the very selectivity that justified the design.

The bystander effect: a feature with a caveat

Tumors are not uniform. Within one mass, some cells display a lot of the target protein and others display little or none. A membrane-permeable payload released from a cleavable linker can diffuse out of the cell it entered and kill neighboring cells that the antibody could never have bound. That bystander killing is one reason conjugates can work against tumors with patchy target expression. The same property cuts the other way, because a drug that can drift to nearby tumor cells can also reach nearby healthy ones, which is part of why bystander-capable agents carry their own toxicity profiles. The effect is a genuine mechanism, not a safety bonus.

Where mechanism meets evidence

Here the story stops being about chemistry and becomes about trial data, and the approved agents do not sit at the same level.

Gemtuzumab ozogamicin, a CD33-directed conjugate carrying a calicheamicin payload, was the first ADC approved, in 2000, then voluntarily withdrawn in 2010 after a confirmatory trial failed to show benefit and raised safety concerns. It returned in 2017 with a fractionated, lower-exposure schedule that the FDA approval describes as improving the benefit-risk balance in CD33-positive acute myeloid leukemia. That arc is a reminder that a sound mechanism can still fail its first real test, and that how a drug is given can change the verdict.

Trastuzumab deruxtecan, which links a HER2 antibody to a topoisomerase I inhibitor with a high DAR and a strong bystander effect, sits at a different evidence tier. In the randomized phase 3 DESTINY-Breast04 trial, it improved both progression-free and overall survival versus physician's-choice chemotherapy in previously treated HER2-low metastatic breast cancer, with long-term follow-up published in Nature Medicine reporting median overall survival of about 22.9 months versus 16.8 months for chemotherapy in the HER2-low population. Enfortumab vedotin, a Nectin-4 conjugate with an MMAE payload, showed a comparable quality of proof in the phase 3 EV-301 trial, where median overall survival reached roughly 12.9 months versus about 9.0 months with chemotherapy after prior platinum and immunotherapy.

The takeaway is that "it is an antibody-drug conjugate" tells you the mechanism, not the strength of the evidence. Some approved agents rest on randomized overall-survival gains against an active comparator; others reached the market on earlier signals and single-arm response rates that a later trial may or may not confirm. When you read about a new conjugate, the questions worth asking are which trial supported it, what it was compared against, whether overall survival or a surrogate endpoint moved, and in which specific population. This article is educational and not medical advice; treatment decisions belong to a person and their own clinician, who can weigh these tradeoffs for an individual situation.